Clinical Trials Browser

Phase 2 × Carcinoma, Hepatocellular × Pharmacogenomic Testing × Clear all

NCT01859182 2014-09-09

Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery

Phase 2 Withdrawn

Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular